CIR Expert Panel Findings: Sept. 24-25
This article was originally published in The Rose Sheet
Chart: Data compiled by the Rose Sheet from information in Cosmetic Ingredient Review reports following the Expert Panel's Sept. 24-25 meeting.
You may also be interested in...
Factors in addition to the rejuvenation of pharmaceutical revenues and biotechnology product failures are likely to pull in opposite directions at the sector’s recovery from the pandemic.
Janssen/Legend Biotech's ciltacabtagene autoleucel and Ipsen's palovarotene are among the latest new medicines that have been submitted for pan-EU approval.
Viatris has reiterated the strength of its biosimilars and complex generics pipeline, highlighting opportunities including biosimilar Eylea, Botox and once-a-month Copaxone.